Table 3.

PI-RADSv2.1 and PI-RADSv2 scores assigned by the three groups of readers

			Benign lesions & ISUP 1 cancers			csPCas
			Experienced seniors	Less experienced seniors	Juniors	Experienced seniors	Less experienced seniors	Juniors
Predefined lesions (N = 240)	PI-RADSv2.1	1	4 [2–12]	4 [1–5]	8 [2–9]	1 [0–2]	1 [0–1]	1 [0–1]
		2	49 [20–61]	20 [14–39]	22 [19–52]	5 [3–6]	0 [0–2]	4 [2–9]
		3	24 [18–29]	15 [12–18]	33 [28–34]	5 [4–7]	4 [3–6]	8 [3–11]
		4	65 [44–86]	96 [90–111]	73 [56–95]	35 [34–39]	39 [38–41]	35 [34–39]
		5	11 [8–15]	13 [11–20]	15 [10–24]	32 [28–36]	33 [30–35]	32 [26–35]
	PI-RADSv2.0	1	3 [1–10]	2 [1–3]	2 [1–7]	1 [0–3]	0 [0–0]	0 [0–1]
		2	28 [17–41]	23 [12–24]	21 [12–23]	3 [2–5]	1 [0–4]	2 [1–3]
		3	26 [21–32]	16 [12–18]	38 [29–44]	5 [5–7]	3 [2–4]	10 [3–12]
		4	87 [49–97]	105 [100–112]	78 [71–97]	38 [34–40]	40 [38–43]	41 [37–42]
		5	11 [9–15]	13 [11–19]	15 [11–24]	32 [28–36]	34 [31–35]	32 [26–35]
Per-lobe analysis (N = 318)	PI-RADSv2.1	1	71 [7–78]	49 [8–58]	50 [22–57]	4 [0–7]	1 [0–3]	4 [2–6]
		2	57 [48–60]	49 [21–75]	40 [37–61]	5 [4, 5]	3 [2–7]	4 [2–5]
		3	33 [22–33]	17 [14–18]	37 [32–47]	5 [3–6]	5 [2–10]	8 [3–10]
		4	60 [46–88]	99 [89–108]	77 [58–96]	36 [32–39]	37 [37–39]	36 [35–38]
		5	18 [11–23]	15 [12–23]	19 [15–35]	43 [36–49]	42 [39–44]	43 [35–49]
	PI-RADSv2.0	1	1 [0–2]	1 [0–2]	1 [0–3]	0 [0–1]	0 [0–0]	0 [0–1]
		2	107 [77–114]	82 [63–89]	65 [58–83]	6 [5–11]	7 [5–9]	6 [4–8]
		3	31 [22–39]	15 [11–23]	37 [28–51]	5 [3–6]	3 [2–4]	8 [3–10]
		4	79 [54–101]	106 [102–112]	81 [72–98]	39 [31–41]	38 [36–41]	38 [36–40]
		5	18 [11–24]	15 [12–22]	19 [15–35]	43 [36–49]	42 [42–46]	43 [36–49]

Data are presented as median number of lesions/lobes [interquartile range]

N Number of lesions/lobes, csPCas Clinically significant prostate cancers, ISUP International society of urological pathology, PI-RADS prostate imaging-reporting and data system